Results 81 to 90 of about 426,237 (354)
T LYMPHOCYTE SUBSETS STUDIED IN A PATIENT WITH TWO ASSOCIATED HEMATOLOGIC NEOPLASIAS – CHRONIC LYMPHOCYTIC LEUKEMIA B AND CHRONIC MYELOID LEUKEMIA [PDF]
Quantification of various cellular subpopulations facilitates the monitoring of hematological diseases, including chronic lymphocytic leukemia. Variations in the proportions of regulatory T cells in peripheral blood have been described in patients with
Georgiana Ene+3 more
doaj +1 more source
Exposure to benzene at work and the risk of leukemia: a systematic review and meta-analysis [PDF]
Background A substantial number of epidemiologic studies have provided estimates of the relation between exposure to benzene at work and the risk of leukemia, but the results have been heterogeneous.
A Le Noir+26 more
core +4 more sources
Hispidulin disrupts the KITENIN/ErbB4 oncogenic complex and inhibits KITENIN‐mediated AP‐1 activity, cell invasion, and aerobic glycolysis. It also suppresses the production of cancer‐associated metabolites and downregulates transcriptional regulators downstream of the KITENIN complex.
Mücahit Varlı+7 more
wiley +1 more source
KAT7‐acetylated and cytoplasm‐translocated G‐protein GαS enhances IL‐6 effect and drives HCC progenitor cell progression. Abstract Background and Aims Hepatocarcinogenesis goes through HCC progenitor cells (HcPCs) to fully established HCC, and the mechanisms driving the development of HcPCs are still largely unknown.
Ye Zhou+15 more
wiley +1 more source
Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukemia and gastrointestinal stromal tumorpatients. Although several in vitro and animal studies demonstrated that imatinib affects immune response, few ...
Rita Santachiara+13 more
doaj +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem+19 more
core +1 more source
Targeting self-renewal pathways in myeloid malignancies [PDF]
A fundamental property of hematopoietic stem cells (HSCs) is the ability to self-renew. This is a complex process involving multiple signal transduction cascades which control the fine balance between self-renewal and differentiation through ...
Copland, M., Sands, W.A., Wheadon, H.
core +2 more sources
Recent Advances in mRNA Delivery Systems for Cancer Therapy
This review systematically investigates the applications of mRNA therapy in cancer treatment, with particular emphasis on nonviral delivery systems, targeting strategies, stimulus‐responsive systems, and local delivery methods. Concluding with a meticulous evaluation, the review sheds light on the prevailing challenges while illuminating promising ...
Zheng Zhang+9 more
wiley +1 more source
Impact of IDH Mutations on DNA Methylation of Acute Myeloid Leukemia Related Genes: A Review Article
Background: Acute myeloid leukemia is one of the deadliest hematologic malignancies that is marked by genetic alterations, abnormal cellular functions, and proliferation. Mutations in isocitrate dehydrogenase genes, particularly isocitrate dehydrogenase
Duha M. Bayram+2 more
doaj +1 more source
Blocking the APRIL circuit enhances acute myeloid leukemia cell chemosensitivity
Resistance to chemotherapy-induced cell death represents a major obstacle in the treatment of acute myeloid leukemia. APRIL (A Proliferation Inducing Ligand) is a member of the tumor necrosis factor superfamily that plays a key role in normal B-cell ...
Désirée Bonci+8 more
doaj +1 more source